PMID- 12813331
OWN - NLM
STAT- MEDLINE
DCOM- 20030717
LR  - 20220310
IS  - 0022-5282 (Print)
IS  - 0022-5282 (Linking)
VI  - 54
IP  - 6
DP  - 2003 Jun
TI  - Prevention of venous thromboembolism in the rehabilitation phase after spinal 
      cord injury: prophylaxis with low-dose heparin or enoxaparin.
PG  - 1111-5
AB  - BACKGROUND: This prospective, multicenter study compared low-dose unfractionated 
      heparin (UFH) with enoxaparin for prophylaxis against venous thromboembolism 
      (VTE) during the rehabilitation phase after spinal cord injury. METHODS: After 2 
      weeks of acute-phase prophylaxis, patients without objective evidence of VTE 
      entered the rehabilitation phase and received up to 6 additional weeks of 
      thromboprophylaxis with either UFH 5,000 U every 8 hours or enoxaparin 40 mg once 
      daily. Patients then underwent repeat bilateral lower extremity duplex 
      ultrasonography. RESULTS: Among 119 patients who completed the rehabilitation 
      phase and had adequate imaging, new VTE was demonstrated in 13 of 60 UFH versus 5 
      of 59 enoxaparin patients (21.7% vs. 8.5%; p = 0.052). Only one patient from each 
      group was discontinued from the study because of bleeding. CONCLUSION: In this 
      nonrandomized comparison, enoxaparin appeared more effective than heparin in the 
      prevention of thromboembolic complications during rehabilitation after spinal 
      cord injury. Both interventions were safe in this population.
CN  - Spinal Cord Injury Thromboprophylaxis Investigators
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Trauma
JT  - The Journal of trauma
JID - 0376373
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Enoxaparin/*administration & dosage/adverse effects
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Heparin/*administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Risk Factors
MH  - Spinal Cord Injuries/complications/*rehabilitation
MH  - Survival Rate
MH  - Thromboembolism/drug therapy/etiology/*prevention & control
MH  - Treatment Outcome
EDAT- 2003/06/19 05:00
MHDA- 2003/07/18 05:00
CRDT- 2003/06/19 05:00
PHST- 2003/06/19 05:00 [pubmed]
PHST- 2003/07/18 05:00 [medline]
PHST- 2003/06/19 05:00 [entrez]
AID - 10.1097/01.TA.0000042159.90102.C2 [doi]
PST - ppublish
SO  - J Trauma. 2003 Jun;54(6):1111-5. doi: 10.1097/01.TA.0000042159.90102.C2.